Your browser doesn't support javascript.
loading
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
Manzo, Julia; Puhalla, Shannon; Pahuja, Shalu; Ding, Fei; Lin, Yan; Appleman, Leonard; Tawbi, Hussein; Stoller, Ronald; Lee, James J; Diergaarde, Brenda; Kiesel, Brian F; Yu, Jing; Tan, Antoinette R; Belani, Chandra P; Chew, Helen; Garcia, Agustin A; Morgan, Robert J; Wahner Hendrickson, Andrea E; Visscher, Daniel W; Hurley, Rachel M; Kaufmann, Scott H; Swisher, Elizabeth M; Oesterreich, Steffi; Katz, Tiffany; Ji, Jiuping; Zhang, Yiping; Parchment, Ralph E; Chen, Alice; Duan, Wenrui; Giranda, Vincent; Shepherd, Stacie P; Ivy, S Percy; Chu, Edward; Beumer, Jan H.
Affiliation
  • Manzo J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Puhalla S; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Pahuja S; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Ding F; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Lin Y; Biostatistics Facility, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Appleman L; Biostatistics Facility, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Tawbi H; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
  • Stoller R; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Lee JJ; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Diergaarde B; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Kiesel BF; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Yu J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Tan AR; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Belani CP; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Chew H; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Garcia AA; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
  • Morgan RJ; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Wahner Hendrickson AE; Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA, USA.
  • Visscher DW; Department of Pathology, Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, USA.
  • Hurley RM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Kaufmann SH; Levine Cancer Institute, Charlotte, NC, USA.
  • Swisher EM; Penn State Cancer Institute, Penn State College of Medicine, Hershey, PA, USA.
  • Oesterreich S; Division of Hematology/Oncology, Department of Medicine, University of California Davis, Sacramento, CA, USA.
  • Katz T; Department of Medicine, Louisiana State University, New Orleans, LA, USA.
  • Ji J; Department of Molecular Pharmacology, City of Hope Beckman Research Institute, Duarte, CA, USA.
  • Zhang Y; Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Parchment RE; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Chen A; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Duan W; Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • Giranda V; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Shepherd SP; Department of Obstetrics and Gynecologic, University of Washington, Seattle, WA, USA.
  • Ivy SP; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Chu E; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Beumer JH; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Cancer Chemother Pharmacol ; 89(5): 721-735, 2022 05.
Article de En | MEDLINE | ID: mdl-35435472
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'ovaire / Tumeurs du sein triple-négatives / Lymphopénie Limites: Female / Humans Langue: En Journal: Cancer Chemother Pharmacol Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Allemagne
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'ovaire / Tumeurs du sein triple-négatives / Lymphopénie Limites: Female / Humans Langue: En Journal: Cancer Chemother Pharmacol Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Allemagne